We investigated the HIV-1 protease molecule for the occurrence of cooperative folding units, i.e. structural units that exhibit a relatively stronger protection against unfolding than do other parts of the molecule. Calculated unfolding penalties are used to delineate folding units. This procedure identifies a folding core in HIV-1 protease, based on an ensemble of denatured states derived from native structures, comprising a spatially close unit of residues 84-91, 74-78 and 22-32, the last of which contains the active site residues D25, T26 and G27. Observed enzyme mutations of HIV-1 protease, either naturally occurring or induced by drug therapy, are found in regions that are not structurally designed to withstand unfolding. These mutations are especially likely to occur in the flap region, a part of the protein which is not essential for the stability of the protein, but does contribute significantly to the stability of proteasedrug complexes. A similar avoidance of structurally protected regions in the reverse transcriptase enzyme is also observed.
Introduction
HIV-1 protease (HIV-1-PR), which belongs to the aspartic proteinase family, is a dimeric protein whose function is to cleave peptide bonds between the immature gag gag-pol protein products. Prevention of this function inhibits the formation of mature capsids in the budding virions and renders the virus harmless. Because HIV-1-PR is an essential enzyme in the viral life cycle, inhibition of the protease can control AIDS. An unprecedented effort to design potent inhibitors against HIV-1-PR has resulted in several highly effective drugs with inhibition constants in the sub-nanomolar range (Wlodawer and Erickson, 1993) . Unfortunately, the initial success of protease inhibitors as effective drugs against HIV has been tempered by the emergence of escape mutants (Baldwin et al., 1995; Ala et al., 1997) , which eventually leads to drug resistance in a monotherapy protocol (Chen et al., 1995; Condra et al., 1995; Erickson, 1995; Roberts, 1995) . The high turnover of virions in the cell, coupled with the error-prone reverse transcriptase enzyme (Wainberg et al., 1996) , ensures that a large and varied population of mutated proteases is always present. However, drug-induced mutations of the protease lead to initially reduced viral levels, but with the sustained production of mature virions the disease persists.
An unusual and important aspect of drug resistance is the inferred cross resistance to other protease inhibitors from exposure to just one drug (Gulnik et al., 1995; Schmit et al., 1996) . As we have shown earlier (Wallqvist et al., 1995; Covell et al., 1998) , many of the earlier protease inhibitors, though chemically varied, utilize a similar binding epitope defined by a limited number of contacts with the protease. This pattern of spatially arranged, hydrophobic and hydrophilic interactions constitutes a set of equally favorable free-energy interactions between the drug molecule and the protease. Thus, if one or more mutants develop as a consequence of drug pressure and modify part of the enzyme binding motif, all other inhibitors using the same binding epitope will lose efficacy.
An important and poorly understood component of designing therapies against a highly mutable HIV-1-PR is how this structure can be so tolerant towards mutations. This question is closely linked to issues regarding stability and folding of globular proteins. Extensive studies have revealed that proteins have several levels of structural complexity, ranging from secondary structure propensities for a few connected amino acids, through domains of hundreds of amino acids, to subunit assemblies involving several different proteins (Creighton, 1992) . Experimentalists studying the folding and associations of the amino acid chain segments prior to native-state formation have identified partial native-like structures among the initial folding events (Dyson and Wright, 1993; Wu et al., 1994; Bai et al., 1995) . These structural elements are commonly referred to as folding domains, foldons or folding cores (Jaenicke, 1991) . The operational definition of these units is the threedimensional structure of the first observable native-like structure that a protein folds to from a denatured state. Mutations within those structural domains that form in the early stages of folding would, presumably, severely limit the formation of a properly folded, functional protein. Our examination of folding domains begins with a discussion of the thermodynamics defining the relation between folded and unfolded states. The native state (N) of a protein exists in equilibrium with all its denatured (U) or partially unfolded states. The native state is populated according to Boltzmann statistics and is governed by the free energy of unfolding:
If we could identify and count all native and denatured states we could in principle calculate the free energy of folding. If all possible denatured states are equally populated the folding/unfolding process is random, but experiments show otherwise. A subset of well defined intermediates often exists in the folding process. Intermediates that acquire their native state early during a folding event may form a folding core.
Amide-hydrogen exchange as determined by NMR is often used to describe partially unfolded structures under native conditions (Raschke and Marqusee, 1998) All amides in a polypeptide chain exchange their protons with water protons when exposed to solvent. The rate of exchange can be studied by deuterating the amide protons and monitoring the decay of the hydrogen signal as a function of time after the protein is first exposed to non-deuterated solvent. Given that the intrinsic rate of exchange is known for an unstructured polypeptide chain (Molday et al., 1972; Bai et al., 1993) , the ratios of the observed rate to the intrinsic rate gives a measure of the free energy cost needed to expose an initially buried amide group (Englander and Mayne, 1992) . Grouping the residues according to exposure free-energy penalties can be used to identify nascent structural features in the protein. These structural assemblies represent our functional definition of folding cores.
The theoretical ab initio descriptions of protein folding are still in their infancy and cannot yet fully address questions about the structure of real proteins. We have recently developed a computational method to identify the existence of stable structural components of a protein and to rank the components' stability (Wallqvist et al., 1997) . Our method is based on the known crystal or NMR structure of a given protein and is not a structure-prediction method. Instead we focus on qualitatively predicting the protection pattern, as derived from the amidehydrogen exchange experiments, and delineating the structural features of folding cores. Critical to this procedure is the description of denatured states accessible to the protein under native conditions. If these states are known, a simple enumeration procedure, together with an estimate of the free energy of these states, can be used to construct the entire ensemble of structures. Since all non-native structures cannot be generated, we use the approach of Freire (1996, 1997) where segments of the native proteins are considered to be in their respective native or non-native configurations. A nonnative segment of the polypeptide chain is simply a stretch of the protein that does not interact with other segments. By dividing a protein into segments, an ensemble of denatured states can be generated by enumerating all possible combinations of these segments. This ensemble of structures, together with a knowledge-based, free-energy scoring scheme, is used to describe the three-dimensional protection patterns for any amino acid in the protein (Wallqvist et al., 1997) .
Our primary aim here is to identify a folding core in the HIV-1-PR and compare those residues with the location of drug-induced amino acid mutations. Although the main focus in this paper is on HIV-1 PR we include a similar mutational analysis of the HIV-1 reverse transcriptase enzyme. In this case we investigate the occurrence of drug-induced mutations in the polymerase domain of the p66 unit. Mutations that are not expressed because of an inability to fold are not observed in nature, as misfolded proteins are rapidly degraded in the cell. Only structural mutations that do not prevent the protein from folding to its native state are detected experimentally. Thus the observed mutants that occur in patients subjected to an HIV drug therapy (Richman, 1993; De Clercq, 1994; Vasudevachari et al., 1996) are properly folded and able to process substrate successfully, albeit with lower efficiency than the original enzyme. Our calculation finds a statistically significant avoidance of drug-induced mutations in regions of the protein that belong to a folding core. These observations may prove useful in rationally selecting inhibitors to HIV-1 protease and reverse transcriptase.
Methods
A detailed description of our method can be found in our previous work (Wallqvist et al., 1997) . A summary of these methods is presented here.
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Calculation of unfolding penalties Unfolding penalties are obtained by forming all possible combinations of interactions between segments of the native X-ray or NMR derived structure Freire, 1996, 1997; Wallqvist et al., 1997) . For a specified amino acid sequence of length n, A n , we employ a minimal segment of length n w to divide the sequence into discrete segments or windows. For the protease monomer unit we used n w ϭ 5 and for the reverse transcriptase polymerase unit n w was set to 10. Each window can be either native (N) or denatured (U), i.e. on or off, so that there are a total of 2 n/n w possible combinations of these segments. The probability of a residue i being in the unfolded/folded state is obtained as a weighted sum over all combinations of segment interactions:
signifies that only configurations kl that contain states in which residue i is denatured/native are included in the sum. The cooperative unfolding penalty of residue i is then defined as
The score of each protein conformation, W, is derived from a knowledge-based scoring scheme discussed below. A satisfactory number of configurations to use is empirically found to be 10 6 -10 7 for most small and large proteins. Most calculations take about 1/3 to 4 CPU hours on a modern workstation.
In comparing two data sets, not necessarily of the same origin, we employ a correlation coefficient r to determine whether a statistically significant correlation exists between the sets (Crow et al., 1960) . As the level of significance used here is at the 1% level, we cannot reject the hypothesis that the data sets are correlated if the p value is less than 0.01.
Identification of folding unit
A folding unit is identified as a three-dimensional region in space whose residues have high penalties for unfolding. We have empirically found that residues which have unfolding penalties in excess of one standard deviation from the mean cooperative unfolding penalty ∆W i F can clearly be identified as being protected. We have adopted this definition as a working criterion for automatically assigning folding units.
Effective protein interactions, W
The score for each combination of segment interactions is based on a single point amino acid description. The knowledgebased interaction score W is derived from known structures in the Protein Data Bank (Abola et al., 1987) . Unbiased averages are obtained by selecting a non-redundant set (Fischer et al., 1995) of 235 non-homologous proteins (Naor et al., 1996) . The coordinate space to calculate W is based on correlations beyond nearest neighbors, namely virtual angles θ between connected triplets of amino acids, dihedral angles φ defined by connected quadruplets of amino acids, structural preferences based on distances r between pairs of 'non-bonded' sites and a pairwise local density term ρ defining available regions in space (Wallqvist et al., 1997) . The total score for a sequence {A} N with coordinates {X} N is then given as
where each individual component has been estimated from frequencies of occurrence in the non-homologous data set and is expressed in units of RT. A weighting scheme for the effective interaction is used that reduces the importance of the secondary structure elements in favor of the non-bonded contacts with α θ ϭ α φ ϭ 0.30/N, α r ϭ 2.80/N and α ρ ϭ 0.50/N.
Sequence similarities
Sequence similarity for HIV-1 protease and reverse transcriptase mutants were obtained by assembling the set of functionally similar sequences from a search of a non-redundant protein database using the native sequence as a query . The default parameters were chosen so that the exact match score was 1.5, and the gap penalty score was set to twice the exact match score (i.e. 3.0). The gap extension or affine penalty was set to 0.1. A running average, based on a sampling window of four residues, is used to report similarity among the aligned sequences. Inspection of sequence similarities for a group of sequences yields low similarities in regions where the sequence variation is high and conversely high similarities indicate a low sequence variation.
Results and discussion

Folding units
The structure of the dimeric enzyme of HIV-1-PR superficially resembles that of other aspartic proteases such as pepsin (Hutchins and Greer, 1991; Wlodawer and Erickson, 1993) . However, whereas pepsin exists as a 326-residue monomer, with two differing domains forming a cleft containing the active site, HIV-1-PR forms a similar groove in the interface between its two 99-residue subunits. As in pepsin, HIV-1-PR has two highly mobile arms of about 10 residues each, which surround and anchor the substrate in the region of the active site. The flaps themselves are not necessary for enzyme activity, although the absence of flaps reduces enzymatic activity (Chatfield and Brooks, 1995; Nicholson et al., 1995; Silva et al., 1996) . The calculated unfolding penalties ∆W i F for HIV-1-PR are displayed in Figure 1 and are color-coded on the ribbon structure of the protease monomer in Figure 2 . HIV-1-PR is a mixed β-sheet structure with one helix per monomer. The active site (residues D25, T26 and G27) is located in a turn region and forms part of the interface between the two monomers. Antiparallel sheets form the outside and the movable flap of the protein. The influence of each monomer on the other's protection pattern against unfolding is very small (data not shown). The changes that do occur are located at the dimer interface, but they do not impart any added protection to the single unit's folding core. Consequently, only data for F and sequence similarity plot for a single monomer of the HIV-1-PR enzyme. The PDB accession code for this structure is 4hvp (Miller et al., 1989) . A segment window of N w ϭ 5 resulted in 10 6.7 configurations considered in the denatured state ensemble. The active site is indicated by boxes in the lower half of the figure. Diamond symbols tag the residues involved in inhibitor binding (Wallqvist et al., 1995) . The cross-line indicates an average of sequence conservation for this protein. Residues that are above this line show an enhanced sequence conservation score; residues below this line are more prone to mutations. (B) The correlation between the sequence conservation measure and the unfolding penalties. The functional residues (residues 46-56) located in the flap region exhibit the weakest correlation between sequence similarity and unfolding penalties. Excluding the functionally important residues [residues 3-9, 97-98 (dimer interface), 2527 (catalytic site), 46-56 (flap region)], the correlation between the unfolding penalties and the sequence variation is statistically significant at the 1% level.
the isolated monomer will be presented. We observe a clear protection pattern comprising residues 22-32, 74-78 and 84-91 (Figure 2) , residues that form a spatially close unit of a helix (84-91) with sheet (74-78) above and another β-strand (22-25) perpendicular to these elements. This core unit contains the active site surrounded by less protected β-sheets and coil regions. The three most unprotected regions in the structure comprise the flap as well as both N-and C-terminal strands. Figure 3 compares the unfolding penalties for two different data sets, both containing HIV-1-PR-drug complexes. The Xray crystal data of Miller et al. (1989) contain an inhibitor based on substrate analogy, MVT101, a reduced amide isostere. Yamazaki et al. (1994) have used NMR studies to find the solution structure of a protease-drug complex containing a cyclic urea-type inhibitor. The calculated unfolding penalties predict similar protection patterns for both data sets, as the solution structure is essentially the same as the crystal structure. Slight deviations in the shape of these curves reflect differences in their 3D coordinates, however, the general position of a maximum and minimum is preserved for these two HIV-1-PR structures. Deviations between the protection patterns occur in the β-sheet at residues 60-70; an exterior region of the molecule associated with large thermal factors in the crystal structure. In Figure 3 , borrowing from Yamazaki et al. (1994) , a bar appears at each residue location having a protected amide hydrogen. These positions correspond to amide hydrogens that were not exchanged after 15 min and identify regions of local stability in HIV-1-PR. The additional protection observed for the flap region of the holo-enzyme may be the result of the stability associated with the flaps' closed position. The flaps are protected in the bound complex; free in solution the apo-enzyme receives no structural protection from the flaps themselves. The sequence similarity plot for the family of HIV-proteases, Crystal structure data were obtained from the 4hvp data set (Miller et al., 1989 ) and the solution NMR structure from the averaged data set deposited in the PDB file 1bvg (Yamazaki et al., 1994) . Amide hydrogens not exchanged after 15 min are also shown (u) as measured by Yamazaki et al. (1994) . The match between the theoretical protection pattern of the folding unit and protected amide hydrogen has a correlation coefficient of 0.62, which is significant at the 1% level (r ϭ 0.62, n f ϭ 45, p Ͻ 0.01), i.e. we cannot discard the hypothesis that the calculated folding unit is compatible with experimental protection data. The locations of the predominant drug-induced mutations found by Vasudevachari et al. (1996) are superimposed on the theoretical protection pattern. The location of each mutation is indicated by a thick bar, the active site residues are indicated by three elongated boxes and residues involved in the general binding motif of protease inhibitors are marked by diamonds. The observation that these mutations avoid the peaks is statistically significant at the 5% level for the data set (r ϭ 0.51, n f ϭ 13, p Ͻ 0.05).
superimposed on the unfolding penalties in Figure 1A , shows four conserved regions among the retroviral sequences. These regions include the structurally important residues 22-32 and 84-91. The flap region between residues 46 and 56 is an example of where a functionally important aspect of the protein is conserved in evolution but does not appear to have any structural importance for the protein fold itself. The correlation between the unfolding penalties and the sequence variability for structurally important residues in Figure 1B is 0.38, which is statistically significant (p Ͻ 0.01) for the number of data points in the set, n f ϭ 78. The region comprising the two outer antiparallel β-sheets between residues 60 and 72 and the single strand 74-78 is structurally important but exhibits comparably less conservation in its sequence composition. As noted above, the HIV-1-PR and other aspartic proteases share several gross structural features (Wlodawer and Erickson, 1993) . With porcine pepsin we used a sequence alignment procedure with gap tolerance to identify the carboxyl portion of this molecule as being the most homologous to HIV-1-PR. We then divided pepsin into two fragments comprising residues 1-173 (I) and 174-327 (II) to investigate the influence of cooperative unfolding penalties on both halves. Since we detected no large effect, as was the case with the dimeric HIV-1-PR, we focused on the protection pattern of the second construct (II). The coordinate set 5pep from the PDB was used in the investigation of pepsin (Cooper et al., 1990) . The same segment window used for the HIV-1-PR calculations was applied here in the calculation of unfolding penalties for pepsin. This protection pattern (data not shown) revealed Fig. 4 . The spatial location of drug-induced mutations in four patients, shown as large, white spheres, superimposed on an C α trace of the protease. The C α trace is colored according to calculated unfolding penalties, as described in the caption for Figure 2 . In this study the protease inhibitor MK-639 (formerly designated L735,524) was administered to four patients over periods of time ranging from 44 to 52 weeks (Condra et al., 1995) . There is a general avoidance of mutations in those regions structurally protected against denaturation. The observation that mutations avoid the peaks is statistically significant at the 1% level for the data set (r ϭ 0.79, n f ϭ 17, p Ͻ 0.01). Note the conservative mutation L24I and L90M close to the active site.
three sharply delineated segments that were protected against unfolding. These two folding units share a striking resemblance, especially in the light of the evolutionary distance between the two species. This unexpected conservation of the same folding core among aspartic proteases suggests that folding might proceed via similar mechanisms.
Drug-induced mutations
It is now well known that monotherapies of protease inhibitors rapidly lead to drug resistance and cross resistance to other protease inhibitor drugs. We have analyzed the occurrence of mutations induced by exposure (Condra et al., 1995) to the protease inhibitor MK-639, a hydroxyethylene isostere analog (Chen et al., 1994) . This drug is now commercially available under the name Crixivan (Indinavir). In a year-long study, Condra et al. (1995) monitored the occurrence of protease mutations in four patients. In Figure 4 we show the unfolding penalties of HIV-1-PR, colored in blue, green and red, to indicate regions of high, intermediate and low protection against unfolding. The location of drug-induced protease mutations for the four patients are shown as white spheres.
Mutations tend not to occur in regions predicted to have the highest unfolding penalties, although conservative mutations do appear close to the active site-two patients both developed an L24I mutant. Less conservative mutations, e.g. hydrophobic to hydrophilic, are absent from these structurally protected regions. In general, mutants consistently avoid both the strongest structurally protected regions and the sequenceconserved regions.
A study of the emergence of drug-resistant mutations in HIV-1-PR isolates by Vasudevachari et al. (1996) shows a pattern of sequence locations prone to mutations. These mutations are indicated in Figure 3 together with predicted unfolding penalties ∆W i F for two protease-drug complexes. In this dataset mutations are less prone to occur in or around the active site triad of D25, T26 and G27. Mutations are otherwise scattered throughout the sequence, but tend to avoid the regions of maximum protection against unfolding. The most densely clustered set of mutations occurs in the flap region; M46, G48 and I50 all exhibit a tendency to mutate. These residues form an energetically important part of the binding epitope on the enzyme and are responsible for much of the binding affinity between enzyme and drug (Wallqvist et al., 1995; Covell et al., 1998) . Since HIV-1-PR obviously can fold and associate without substrate and the flap region does not contribute strongly to the enzyme's stability, mutations of flap residues provide an effective means for the virus to evade administered protease drugs.
As we have shown in previous work (Wallqvist et al., 1995; Covell et al., 1998) , there is a striking similarity in the binding epitope that each unique protease inhibitor utilizes for binding to the HIV-1-PR enzyme. The amino acids of HIV-1-PR involved in this general motif are indicated in Figure 3 . Although many of these amino acids are located in both structurally and functionally important regions, some are not and can be mutated relatively easily, apparently without drastic structural or functional consequences. Modifying just one of these residues in contact with the inhibitor can reduce the overall binding strength by a few kcal/mol (Gulnik et al., 1995; Wallqvist et al., 1995) , thus sharply reducing the potency of any drug bound by this epitope. A drug design which considered both conserved structural and functional elements of a target could possibly mitigate the effects of drug resistance.
Drug-induced mutations in HIV-1 reverse transcriptase.
An additional target for AIDS drug therapies is the reverse transcriptase (RT) enzyme of the human immunodeficiency virus. This enzyme is responsible for translating the viral RNA to be incorporated in the human host cell into DNA. The in vivo composition of RT is a heterodimer consisting of two subunits identified as p66 and p51. The larger subunit contains a polymerase and an RNaseH domain, with the smaller unit identical with the larger except for the lack of the RNaseH function (Erickson and Burt, 1996) .
The observed in vivo mutations induced by drug therapy are essentially all located in the polymerase domain of the p66 unit (Richman, 1993; De Clercq, 1994) . We have calculated the unfolding penalties for the excised polymerase unit, comprising amino acids 1-243, in the absence of the remainder of the protein. Thus we are not accounting for domain-domain interactions in either the subunit or the complete RT complex. The graph in Figure 5 correlates regions of strong cooperative stabilization with enhanced unfolding penalties as a function of sequence position. The region encompassing amino acids The PDB call name for the structural coordinates is 1rth (Ren et al., 1995) . The calculation was performed only on the first 243 amino acid entries of the p66 subunit, all other coordinates were deleted. A window size of 10 was used, incorporating 10 8.52 configurations in the enumeration of non-native states. The locations of observed mutations arising in drug therapies are indicated both for nucleoside and non-nucleoside inhibitors. The full list of the mutations was taken from the WWW page http:// www.intmedpress.com/iavn/4_6/res1dom.html. Statistical analysis shows that the folding core is anti-correlated with the location of the mutations, i.e. there is an avoidance of the mutations to occur at cooperatively protected regions in the structure (r ϭ 0.75, n f ϭ 27, p Ͻ 0.01).
115-130 and 155-160 delineates two distinct segments that may be an independent folding core of the polymerase domain.
Two broad classes of inhibitors have been developed against the HIV-1 RT enzyme (Richman, 1993; De Clercq, 1994) : nucleoside analogs (e.g. AZT and ddI) and non-nucleoside analogs (e.g. nevirapine and TIBO), both of which bind to the enzyme in different locations. It is well known that exposure to any one of the available RT inhibitors can lead to rapidly emerging drug resistance. The observed in vivo mutations caused by the different classes of inhibitors are indicated in Figure 5 . The non-overlapping occurrence of mutations for the two drug classes has created the possibility of combination therapies of both nucleoside and non-nucleoside drugs taken together to combat drug resistance.
Our initial observation of drug-induced mutations in the protease system is also borne out in the RT system. Thus the nucleoside-resistant mutations tend to avoid the putative folding core and other regions of local stability, as indicated by the regions of maximum unfolding penalties in Figure 5 . The deviation from this observation occurs for the relativelyfrom a structural point of view-conservative tyrosine to phenylalanine mutation Y115F. Mutations are also developed by both types of drugs in the sequence region 179-190. This region encompasses the β-sheet that encloses the binding cavity, is in direct contact with the bound drug and should be susceptible to mutations. Our calculations indicate that the 179-190 region is cooperatively stabilized; however this stability does not appear sufficient to avoid mutations. A sequence comparison of 10 retroviral RTs (Barber et al., 1990) from different viruses indicates that this region has high sequence variability in spite of its apparent cooperative stabilization [the RT sequences studied were human immunodefici-ency virus, Rous sarcoma virus, equine infectious anemia virus, bovine leukemia virus, Visna virus (strain 1514), Moloney murine leukemia virus, Caprine arthritis encephalitis virus, human T-cell lymphotropic type I, mouse mammary tumor virus and simian Mason-Pfizer D-type rv].
Drug-induced mutations in HIV-1-RT appear to obey two simple rules: they may occur in regions with high sequence variability (a primary consideration), and they tend to avoid regions that are cooperatively stabilized. Both conditions should be present, but low sequence variation takes precedence. For example, regions of low cooperative stability, like amino acids 220-230 which have a low sequence variability, are consequently not prone to mutations. Many amino acids in the 220-230 segment are essential for RT function and mutations among these residues can completely destroy the enzyme activity (Erickson and Burt, 1996) . Regions of high folding stability which are also characterized by low sequence variability, are thus not suitable sites for mutations.
Conclusion
Our methodology for studying amino acid residue protection against unfolding in globular proteins has been applied to the HIV-1-PR and HIV-1-RT enzymes. This procedure identifies cooperative stabilization of specific segments of a protein.
Stabilization is provided by favorable interactions between residues within the generated ensemble of denatured states. The cooperative stabilization of segments into their native three-dimensional structure permits identification of a folding core. Since even under native conditions the chance of finding a protein in a denatured state is finite, a physical correspondence to a folding core would be the last remnant of native-like tertiary structure to disappear upon unfolding. Similarly, it would be the first native-like tertiary structure to appear upon folding under these conditions.
In HIV-1-PR clearly identifiable regions of tertiary structure are involved in forming a folding core. The protease monomer folding core is not strongly influenced by the other monomer; dimerization is not essential for stabilization of either monomer. The folding unit is composed of contiguous sequence segments that form a compact three-dimensional structure comprising residues 84-91, 74-78 and a segment 22-32 which contains the essential active site residues Asp25, Thr26 and Gly27. This core's three-dimensional structure is repeated in a distantly related aspartic protease, porcine pepsin. The conservation of folding cores in the evolution of protein design and function may be more important than sequence conservation. Thus sequences, or parts of sequences, with low homology may exhibit a striking structural resemblance.
The impact of protease inhibitor drugs on AIDS has been dramatic, yet the sustained therapeutic success has been hampered by the rapid appearance of escape mutants in monotherapies. Cross resistance to other protease drugs is often accompanied by the emergence of these mutant proteases. Drug-induced mutations tend to avoid regions involving the folding core of the HIV-1-PR (Condra et al., 1995) . A cluster of mutations in the flap region can be particularly devastating as these mutations do not reduce the stability of the protein per se but instead modify the general enzyme-drug binding motif. Likewise for the HIV-1-RT there is an avoidance for mutations within its folding core. Incorporation of these considerations regarding protein stability and binding motifs could provide powerful guidelines for rational, structure-based drug designs.
